舒洛地特治疗早期糖尿病肾病白蛋白尿

Treatment of Sulodexide on Albuminuria in Early Diabetic Nephropathy

目的观察舒洛地特治疗早期糖尿病肾病(DN)的白蛋白尿临床疗效。方法收集早期糖尿病患者65例,随机分成2组,对照组30例,治疗组35例。2组疗程均为8周。对照组,口服氯沙坦片50m g/d,4周。治疗组在常规治疗基础上(氯沙坦钾片50mg,1次/d)加舒洛地特给予600LSU,qd,iv,1次/d,连续2周后,改为舒洛地特片200 mg/d使用6周(共8周)。结果24 h尿蛋白定量均较治疗前明显降低(P<0.05或P<0.01),联合治疗组降低优于对照组。结论舒洛地特能有效改善早期糖尿病肾病白蛋白尿。

ObjectiveTo study the clinical effect of Sulodexide on albuminuria in early diabeticnephropathy.Methods65 cases of patients with early diabetic nephropathy were randomly divid-ed to a control group including 30 cases and a treatment group including 35 cases. Both groups havethe treatment 8 weeks. The control group orally take Losartan 50 mg/d for 4 weeks. The treatmentgroup on the basis of normal treatment（Losartan potassium 50 mg,one time/d）,adds Sulodexide600 LSU,qd,iv,one time/d,after 2 weeks,changes to use Sulodexide tablet 200 mg/d for 6 weeks（totally 8 weeks）.ResultsAfter treatment,B2-MG,BUN,CREA and 24-hour urinary proteinis significantly lower than that before treatment for both groups（P0. 05 or P0. 01）. These indexesof treatment group are better than those of control group.ConclusionSulodexide can relieve albu-minuria effectively in early diabetic nephropathy.